Celligenics develops CGN1, a cell-free regenerative extract derived from a unique sub-population of stem cells, which stimulates cell repair and regeneration. This technology significantly accelerates wound healing for chronic ulcers and enhances skin health through biologically active ingredients, addressing the slow recovery and ineffectiveness of traditional treatments.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic ulcers, often affecting individuals with poor circulation, heal slowly and require extended treatment, leading to frequent hospitalizations and high healthcare costs. Traditional skincare products offer temporary improvements but lack lasting effects on skin health.
Solution
Celligenics has developed CGN1, a cell-free regenerative extract derived from a unique sub-population of stem cells, designed to stimulate cell repair and regeneration. This platform technology is being applied to wound healing and cosmeceuticals. In wound healing, CGN1 aims to accelerate the healing rate of chronic ulcers, reducing hospitalization and treatment costs. In cosmeceuticals, CGN1 is formulated into a skincare blend with biologically active ingredients intended to create lasting changes in the skin, rather than just temporary improvements.
Target Audience
The primary target audience includes patients suffering from chronic ulcers, individuals seeking advanced skincare solutions, and healthcare providers looking for innovative regenerative medicine technologies.
Features
- CGN1: A cell-free regenerative extract derived from a unique sub-population of stem cells.
- Proprietary extraction process achieving stem cell purity levels of over 90%.
- Wound healing application: Formulated to double the rate of wound healing in chronic ulcers.
- Cosmeceutical application: Skincare blend designed for lasting skin health improvements.
- Scalable manufacturing processes for cost-effective production.